A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients

A.C. Chen; Andrew Martin; Robyn A. Dalziell; Catriona McKenzie; Patricia Lowe; Josette Eris; Richard A Scolyer; Haryana M. Dhillon; Janette L. Vardy; V.A. Bielski; Gary M. Halliday; Diona L. Damian

doi:10.1111/bjd.14662

Related publications

Letter2016

Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’

Diona L. Damian, Andrew Martin, Richard A Scolyer, A.C. Chen, Gary M. Halliday

Article2023

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients

Nicholas Allen, Andrew Martin, Victoria A. Snaidr, Renee Eggins, Alvin H Chong, Pablo Fernández‐Peñas, Douglas L. Gin, Shireen Sidhu, Vanessa L. Paddon, Leith Banney, Adrian Lim, Edward Upjohn, Helmut Schaider, Aparna D. Ganhewa, Jennifer Nguyen, Catriona McKenzie, Saurabh Prakash, Catriona McLean, Alistair Lochhead, Jan Ibbetson, Andrew Dettrick, Anthony Landgren, Katherine J. Allnutt, Clare Allison, Rachael Davenport, Blake P. Mumford, Brittany Wong, Brendan Stagg, Alexander Tedman, Hannah Gribbin, Harrison A. Edwards, Nicholas De Rosa, T. D. Stewart, Brent J. Doolan, Yonatan Kok, Kate Simpson, Zhi M. Low, Tom Kovitwanichkanont, Richard A Scolyer, Haryana M. Dhillon, Janette L. Vardy, Steven J. Chadban, David G. Bowen, Andrew C. Chen, Diona L. Damian

Article2015

A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients

Discussion(0)

Related publications

Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention

Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo

Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.